Has Enrique Hanabergh, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,207,592 in general payments to Enrique Hanabergh, MD across 395 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Enrique Hanabergh, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Enrique Hanabergh, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Enrique Hanabergh, MD

Cardiovascular Disease · Aventura, FLNPI 1821087156

Payments from drug & device makers

$2,207,592in general payments, 2019–2025

Across 395 payments — averaging $5588.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Merck$1.1M
Chiesi USA, Inc.$470K
Pfizer$248K
Gilead$197K
Teva Pharmaceuticals USA, Inc.$78K
Otsuka Pharmaceutical Development & Commercialization, Inc.$37K
plus $35K from 36 others

$27,768in research payments, 2019–2025

Across 6 payments — averaging $4627.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Arbor Pharmaceuticals, Inc.$23K
Eli Lilly$5K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Merck	31	$1,142,756
Chiesi USA, Inc.	44	$470,311
Pfizer	45	$248,026
Gilead	6	$196,920
Teva Pharmaceuticals USA, Inc.	5	$77,800
Otsuka Pharmaceutical Development & Commercialization, Inc.	4	$37,198
GSK	5	$28,731
Medtronic(2 entities)	11	$1,254
Johnson & Johnson	37	$672
Novartis	23	$414
Sanofi-aventis U.S. LLC	21	$367
E.r. Squibb & Sons, L.L.C.	19	$358
Novo Nordisk	17	$310
Amarin Pharma, Inc.	16	$302
AstraZeneca	12	$210
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	11	$210
Boehringer Ingelheim	9	$203
Amgen	9	$174
Regeneron Healthcare Solutions, Inc.	7	$155
Cvrx, Inc.	6	$119
Esperion Therapeutics, Inc.	6	$108
AbbVie(2 entities)	6	$99
Arbor Pharmaceuticals, Inc.	6	$89
Actelion Pharmaceuticals US, Inc.	3	$85
Abbott	4	$71
Kowa Pharmaceuticals America, Inc.	4	$67
Exact Sciences	3	$67
Boston Scientific	3	$57
Biohaven Pharmaceutical Holding Company Ltd.	2	$55
Astellas Pharma US Inc	3	$53
Mylan Specialty L.p.	2	$53
Otsuka America Pharmaceutical, Inc.	2	$43
Heartflow, Inc.	1	$42
Genentech USA, Inc.	2	$37
IBSA Pharma Inc.	2	$36
Eisai Inc.	2	$34
Alnylam Pharmaceuticals Inc.	1	$20
Biohaven Pharmaceuticals, Inc.	1	$20
Kiniksa Pharmaceuticals International, PLC	1	$19
Philips North America LLC	1	$17
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$16
Lexicon Pharmaceuticals, Inc.	1	$15

How this compares

$2,207,592 in reported general payments places this provider in the 95th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida →

Medicare billing

Part B allowed, 2024

$86,203

Medicare patients

374

Services billed

1,289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in Aventura

Eric SpivackAventura$7.1M
Steven RappAventura$1.6M
Michael KorenGainesville$31M
Seth BaumBoca Raton$11.1M
Alexis GutierrezHialeah$8M
William OneillNaples$4.6M
Rafik AbadierInverness$4.4M
Alvaro MurciaPembroke Pines$4M
David HotchkissPort Charlotte$4M
Ferris GeorgeSt Augustine$3.8M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →